PPARγ and stress: Implications for aging

Experimental Gerontology

Volumn 48, Issue 7, 2013, Pages 671-676

  Ulrich Lai, Yvonne M ^a   Ryan, Karen K ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Aging; Brain; Corticosterone; HPA axis; PPAR ; Stress

Indexed keywords

CORTICOSTERONE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE;

ADIPOGENESIS; AGING; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; BINDING AFFINITY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN SIZE; CEREBROVASCULAR ACCIDENT; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG PROTEIN BINDING; GLUCOSE METABOLISM; HIPPOCAMPUS; HORMONE ACTION; HORMONE METABOLISM; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INFLAMMATION; MENTAL STRESS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PHYSIOLOGICAL STRESS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RISK REDUCTION; SIGNAL TRANSDUCTION; TACHYCARDIA; TRANSCRIPTION REGULATION; WHITE ADIPOSE TISSUE;

AGE FACTORS; AGING; ANIMALS; BRAIN; COGNITION DISORDERS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; PITUITARY-ADRENAL SYSTEM; PPAR GAMMA; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84879019473     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2012.08.011     Document Type: Article

References (60)

1. Aguilera G. HPA axis responsiveness to stress: implications for healthy aging. Exp. Gerontol. 2011, 46:90-95.
2. Argmann C., Dobrin R., Heikkinen S., Auburtin A., Pouilly L., Cock T.A., Koutnikova H., Zhu J., Schadt E.E., Auwerx J. Ppargamma2 is a key driver of longevity in the mouse. PLoS Genet. 2009, 5:e1000752.
3. Baker P.R., Lin Y., Schopfer F.J., Woodcock S.R., Groeger A.L., Batthyany C., Sweeney S., Long M.H., Iles K.E., Baker L.M., Branchaud B.P., Chen Y.E., Freeman B.A. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J. Biol. Chem. 2005, 280:42464-42475.
4. Barbieri M., Bonafe M., Rizzo M.R., Ragno E., Olivieri F., Marchegiani F., Franceschi C., Paolisso G. Gender specific association of genetic variation in peroxisome proliferator-activated receptor (PPAR)gamma-2 with longevity. Exp. Gerontol. 2004, 39:1095-1100.
5. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu. Rev. Med. 2002, 53:409-435.
6. Blass J.P., Gibson G.E., Hoyer S. Metabolism of the aging brain. Advances in Cell Aging and Gerontology 1997, 109-128. JAI Press Inc., London. P.S. Timiras, E.E. Bittar, M.P. Mattson, J.W. Geddes (Eds.).
7. Chapman D.P., Perry G.S. Depression as a major component of public health for older adults. Prev. Chronic Dis. 2008, 5:A22.
8. Choi J.H., Banks A.S., Estall J.L., Kajimura S., Bostrom P., Laznik D., Ruas J.L., Chalmers M.J., Kamenecka T.M., Bluher M., Griffin P.R., Spiegelman B.M. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
9. Corton J.C., Brown-Borg H.M. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60:1494-1509.
10. Eissa Ahmed A.A., Al-Rasheed N.M., Al-Rasheed N.M. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 2009, 20:635-642.
11. Escribano L., Simon A.M., Perez-Mediavilla A., Salazar-Colocho P., Del Rio J., Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 2009, 379:406-410.
12. Ferrari E., Cravello L., Muzzoni B., Casarotti D., Paltro M., Solerte S.B., Fioravanti M., Cuzzoni G., Pontiggia B., Magri F. Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates. Eur. J. Endocrinol. 2001, 144:319-329.
13. Garcia-Bueno B., Madrigal J.L., Lizasoain I., Moro M.A., Lorenzo P., Leza J.C. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol. Psychiatry 2005, 57:885-894.
14. Garcia-Bueno B., Caso J.R., Perez-Nievas B.G., Lorenzo P., Leza J.C. Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 2007, 32:1251-1260.
15. Garcia-Bueno B., Madrigal J.L., Perez-Nievas B.G., Leza J.C. Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats. Endocrinology 2008, 149:1969-1978.
16. Garrido P. Aging and stress: past hypotheses, present approaches and perspectives. Aging Dis. 2011, 2:80-99.
17. Garrido P., De Blas M., Gine E., Santos A., Mora F. Aging impairs the control of prefrontal cortex on the release of corticosterone in response to stress and on memory consolidation. Neurobiol. Aging 2012, 33(827):e821-e829.
18. Haramizu S., Ota N., Hase T., Murase T. Aging-associated changes in physical performance and energy metabolism in the senescence-accelerated mouse. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66:646-655.
19. Hauser S., Adelmant G., Sarraf P., Wright H.M., Mueller E., Spiegelman B.M. Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 2000, 275:18527-18533.
20. Herman J.P., Larson B.R., Speert D.B., Seasholtz A.F. Hypothalamo-pituitary-adrenocortical dysregulation in aging F344/Brown-Norway F1 hybrid rats. Neurobiol. Aging 2001, 22:323-332.
21. Izawa Y., Takahashi S., Suzuki N. Pioglitazone enhances pyruvate and lactate oxidation in cultured neurons but not in cultured astroglia. Brain Res. 2009, 1305:64-73.
22. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
23. Jiang Q., Heneka M., Landreth G.E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 2008, 22:1-14.
24. Ji-Rong Y., Bi-Rong D., Chang-Quan H., Zhen-Chan L., Hong-Mei W., Yan-Ling Z., Mattis T.A. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians. Arch. Med. Res. 2009, 40:411-415.
25. Joels M., Karst H., Alfarez D., Heine V.M., Qin Y., van Riel E., Verkuyl M., Lucassen P.J., Krugers H.J. Effects of chronic stress on structure and cell function in rat hippocampus and hypothalamus. Stress 2004, 7:221-231.
26. Johnson W., Harris S.E., Starr J.M., Whalley L.J., Deary I.J. PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes. Neurosci. Lett. 2008, 434:50-55.
27. Kitraki E., Karandrea D., Kittas C. Long-lasting effects of stress on glucocorticoid receptor gene expression in the rat brain. Neuroendocrinology 1999, 69:331-338.
28. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995, 83:813-819.
29. Kukolja J., Thiel C.M., Wolf O.T., Fink G.R. Increased cortisol levels in cognitively challenging situations are beneficial in young but not older subjects. Psychopharmacology (Berl) 2008, 201:293-304.
30. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
31. Loane D.J., Deighan B.F., Clarke R.M., Griffin R.J., Lynch A.M., Lynch M.A. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 2009, 30:920-931.
32. Lupien S., Lecours A.R., Lussier I., Schwartz G., Nair N.P., Meaney M.J. Basal cortisol levels and cognitive deficits in human aging. J. Neurosci. 1994, 14:2893-2903.
33. Lupien S., Lecours A.R., Schwartz G., Sharma S., Hauger R.L., Meaney M.J., Nair N.P. Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol. Aging 1996, 17:95-105.
34. Magri F., Terenzi F., Ricciardi T., Fioravanti M., Solerte S.B., Stabile M., Balza G., Gandini C., Villa M., Ferrari E. Association between changes in adrenal secretion and cerebral morphometric correlates in normal aging and senile dementia. Dement. Geriatr. Cogn. Disord. 2000, 11:90-99.
35. Mizoguchi K., Ikeda R., Shoji H., Tanaka Y., Maruyama W., Tabira T. Aging attenuates glucocorticoid negative feedback in rat brain. Neuroscience 2009, 159:259-270.
36. Moreno S., Farioli-Vecchioli S., Ceru M.P. Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004, 123:131-145.
37. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 2008, 28:9287-9296.
38. Ohshima T., Koga H., Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem. 2004, 279:29551-29557.
39. 2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J. Neurochem. 2009, 109:1800-1811.
40. Raz N., Rodrigue K.M. Differential aging of the brain: patterns, cognitive correlates and modifiers. Neurosci. Biobehav. Rev. 2006, 30:730-748.
41. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
42. Rosa A.O., Kaster M.P., Binfare R.W., Morales S., Martin-Aparicio E., Navarro-Rico M.L., Martinez A., Medina M., Garcia A.G., Lopez M.G., Rodrigues A.L. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1549-1556.
43. Ruan X., Zheng F., Guan Y. PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal. Physiol. 2008, 294:F1032-F1047.
44. Ryan K.K., Grayson B.E., Jones K.R., Schneider A.L., Woods S.C., Seeley R.J., Herman J.P., Ulrich-Lai Y.M. Physiological responses to acute psychological stress are reduced by the PPARgamma agonist rosiglitazone. Endocrinology 2012, 153:1279-1287.
45. Schopfer F.J., Lin Y., Baker P.R., Cui T., Garcia-Barrio M., Zhang J., Chen K., Chen Y.E., Freeman B.A. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:2340-2345.
46. Semple R.K., Chatterjee V.K., O'Rahilly S. PPAR gamma and human metabolic disease. J. Clin. Invest. 2006, 116:581-589.
47. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 2005, 130:685-696.
48. Sung B., Park S., Yu B.P., Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 2004, 59:997-1006.
49. Sung B., Park S., Yu B.P., Chung H.Y. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Exp. Gerontol. 2006, 41:590-599.
50. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994, 79:1147-1156.
51. Ulrich-Lai Y., Engeland W. Adrenal splanchnic innervation modulates adrenal cortical responses to dehydration stress in rats. Neuroendocrinology 2002, 76:79-92.
52. Ulrich-Lai Y.M., Herman J.P. Neural regulation of endocrine and autonomic stress responses. Nat. Rev. Neurosci. 2009, 10:397-409.
53. van Beekum O., Fleskens V., Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 2009, 17:213-219.
54. Wang N., Verna L., Chen N.G., Chen J., Li H., Forman B.M., Stemerman M.B. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J. Biol. Chem. 2002, 277:34176-34181.
55. Wise P.M., Herman J.P., Landfield P.W. Neuroendocrine aspects of the aging brain. Advances in Cell Aging and Gerontology 1997, 193-241. JAI Press Inc., London. P.S. Timiras, E.E. Bittar, M.P. Mattson, J.W. Geddes (Eds.).
56. Yaffe K., Kanaya A.M., Lindquist K., Hsueh W.C., Cummings S.R., Beamer B., Newman A., Rosano C., Li R., Harris T. PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol. Aging 2008, 29:78-83.
57. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 2003, 278:498-505.
58. Zhang L., Xie P., Wang J., Yang Q., Fang C., Zhou S., Li J. Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension. J. Biol. Chem. 2010, 285:13666-13677.
59. Zhang H.L., Xu M., Wei C., Qin A.P., Liu C.F., Hong L.Z., Zhao X.Y., Liu J., Qin Z.H. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferator-activated receptor gamma-mediated suppression of nuclear factor-kappaB signaling pathway. Neuroscience 2011, 176:381-395.
60. Zierath J.R., Ryder J.W., Doebber T., Woods J., Wu M., Ventre J., Li Z., McCrary C., Berger J., Zhang B., Moller D.E. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 1998, 139:5034-5041.